STAT3 and neoplasm: Targeting IL-6R and IL-11R in mouse models can significantly reduce STAT3 activation and enhance the effect of chemotherapy agents such as gemcitabine in tumor killing effect, suggesting that the interleukin pathway may be a good therapeutic target (91).